Bumecard 1: Each tablet contains Bumetanide BP 1mg
Bumecard 5: Each tablet contains Bumetanide BP 5 mg
Bumecard 2 IV/IM Injection: Each 4 ml ampoule contains Bumetanide BP 2 mg.
Bumetanide inhibits sodium reabsorption in the ascending limb of the loop of Henle. Reabsorption of chloride in the ascending limb is also blocked by Bumetanide.
Bumetanide may have an additional action in the proximal tubule. Since phosphate reabsorption takes place largely in the proximal tubule, phosphaturia during Bumetanide induced diuresis is indicative of this additional action. This proximal tubular activity does not seem to be related to an inhibition of carbonic anhydrase. Bumetanide does not appear to have a noticeable action on the distal tubule.
1 mg in the morning , repeated after 6-8 hours if necessary, In severe cases , 5 mg daily increased by 5 mg every 12-24 hours according to response. Elderly , 500 micrograms daily may be sufficient.
By IV Injection : 1-2 mg, repeated after 20 minutes if necessary. Elderly, 500 micrograms (1 ml of Bumecard) daily may be sufficient.
By IV Infusion : 2-5 mg over 30-60 minutes.Elderly, 500 micrograms (1 ml of Bumecard) daily may be sufficient.
By IM Injection : 1 mg initially then adjusted according to response , Elderly 500 micrograms (1 ml of Bumecard) daily may be sufficient.
Paediatric use: Safety and effectiveness in paediatric patients below the age of 18 have not been established.
Others (ECG changes (0.4 %), musculoskeletal pain (0.2 %), Abdominal pain (0.2 %), renal failure (0.1%), thrombocytopenia (0.2%) etc.
Lactation: It is not known wheather this drug is excreted in human milk.
Probenecid: should not be administered concurrently with Bumetanide.
Indomethacin: Concurrent therapy with Bumetanide is not recommended.
Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels.
Anticoagulants: Interaction studies in humans have shown Bumetanide to have no effect on warfarin metabolism.
Bumecard 5: Each box contains 3 alu-PVDC strips of 10 tablets.
Bumecard 2 IV/IM Injection : Each box contains 5 ampolues of 4 ml solution for injection .